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Abstract: Incretin mimetics are set to become a mainstay of
type 2 diabetes treatment. By acting on the pancreas and brain,
they potentiate insulin secretion and induce weight loss to
preserve normoglycemia. Despite this, incretin therapy has
been associated with off-target effects, including nausea and
gastrointestinal disturbance. A novel photoswitchable incretin
mimetic based upon the specific glucagon-like peptide-1 recep-
tor (GLP-1R) agonist liraglutide was designed, synthesized,
and tested. This peptidic compound, termed LirAzo, possesses
an azobenzene photoresponsive element, affording isomer-
biased GLP-1R signaling as a result of differential activation of
second messenger pathways in response to light. While the
trans isomer primarily engages calcium influx, the cis isomer
favors cAMP generation. LirAzo thus allows optical control of
insulin secretion and cell survival.
Type 2 diabetes (T2D) currently affects approximately 8%
of the global adult population. This syndrome can be best
described as a failure of the pancreatic beta-cell mass to
adequately compensate for peripheral insulin resistance by
secreting sufficient hormone.[1] The resultant dysregulated
glucose and lipid metabolism underlie a range of undesirable
sequelae, including heart, vascular, nerve, and renal dis-
eases.[2] In the majority of cases, adequate control over T2D
can be achieved through lifelong medication together with
diet and exercise. To this end, incretin mimetics, i.e., drugs
based upon gut-derived glucose-lowering hormones, have
rapidly become first-line antidiabetics for the maintenance of
normoglycemia.[3] Indeed, long-acting analogues of the endo-
genously released incretin glucagon-like peptide-1 (GLP-1)
have been shown to: 1) potently augment insulin release in
a glucose-dependent manner; 2) induce profound weight loss
through actions on the brain; and 3) slow down beta-cell
failure through pro-survival/anti-apoptotic effects.[4] While
such traits undoubtedly make the incretin class attractive
candidates for the management of T2D, adverse effects have
already been associated with their use, including an increased
risk of pancreatitis (causality unclear),[5] gastrointestinal
disturbance, and nausea.[6] Methods for targeting drug activity
to the tissue of interest would thus provide a desirable
refinement to the treatment of T2D with incretin mimetics.
Photopharmacology is well-adapted for these purposes, since
it harnesses the spatiotemporal precision of light to finely
control biological processes (see Figure S1 in the Supporting
Information)[7] and is applicable to the pancreas.[8]
Building on previous studies with photocontrolled chigo-
lin, nNOS derivatives, and fluorescence reporter peptides,[9]
we reasoned that optical control over the incretin axis could
be afforded by installing photoresponsive elements on
liraglutide, a stabilized GLP-1 analogue (Figure 1a,b).[6,10]
Figure 1. Logic, design, and primary structure of LirAzo. a) The liraglu-
tide NMR structure (PDB ID: 4apd) served as a template for the
synthesis of LirAzo, which differs in the placement of AMPP (red)
between the helices (a=azologization). b) cis-AMPP and trans-AMPP
are formed upon illumination with UV and blue light, respectively.
c) The amino acid sequence of LirAzo, showing the replacement of
22G–23Q by AMPP (p=palmitoyl).
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To reliably access glucagon-like peptide-1 receptor (GLP-1R)
photoactivation through geometric alterations to ligand
structure, an azobenzene photoswitch comprising the amino
acid [3-(3-aminomethyl)phenylazo]phenylacetic acid
(AMPP)[9b,11] was incorporated into liraglutide. To minimize
disruption to helix folding, AMPP was inserted as a bridge
between the two a-helices of liraglutide (PDB ID: 4apd;
Figure 1a), replacing amino acids 22G-23Q, to obtain LirAzo
by solid-phase peptide synthesis (Figure 1c and Table S1 in
the Supporting Information). NMR spectra were recorded
with 35% aqueous [D3]trifluoroethanol to prevent aggrega-
tion, as previously reported (PDB ID: 1d0r),[12] thus providing
further evidence for correct folding and in vitro behavior of
LirAzo.
To compare LirAzo with liraglutide, we synthesized
a benchmark peptide, termed “Lira”, in which the palmitoyl
(gEp) moiety at 26K was omitted. This residue, originally
introduced to improve plasma binding and half-life in vivo,[6]
is unnecessary for in vitro studies.
The cis–trans isomerization of LirAzo was initially
assessed by UV/Vis spectroscopy (Figure 2a). Switching
kinetics in response to blue (l= 440 nm; cis!trans) and
UV (l= 330 nm; trans!cis) light were robust and fast, with
no evidence of degradation or bleaching (Figure 2b; see
Figure S2 and Table S2 in the Supporting Information).
LirAzo displayed remarkable bistability when switched to
its cis state and subsequently left in the dark (Figure 2c), thus
allowing pre-illuminated LirAzo to be applied to tissue. GLP-
1 binds the GLP-1R through interactions with both the
extracellular (22G–37G) and lipid bilayer (7TM domain)
portions (Figure S3).[13] From this, it can be predicted that
cis- and trans-LirAzo divergently activate receptor signaling
by altering one or both of the helical interactions, rather than
providing a simple “on–off” switch.
Accompanying alterations to peptide secondary and
tertiary structure were confirmed by CD spectroscopy (Fig-
ure S4). While Lira exhibits CD signals typical of a-helix
possession, only the trans isomer of LirAzo shows signals
similar to those of Lira. cis-LirAzo, however, features
diverging CD signals (weak maximum at l= 189 nm) con-
sistent with the predicted (partial) helix unfolding (Fig-
ure S4a). Moreover, in the near-UV region, the signal of cis-
LirAzo rises to a maximum (l= 326 nm) that can be assigned
to the cis-azobenzene moiety in a chiral environment (see
Figure S4b).[14] NMR spectra for Lira and LirAzo unambig-
uously demonstrate differences in AMPP and folding behav-
ior upon cis–trans isomerization (see the Supporting Infor-
mation for full NMR spectra and Table S3 for annotation).
These findings are of interest, since changes in the secondary
and tertiary structure dictate key pharmacological properties,
including half-life, permeability, and mode of action. While
the former two require complex pharmacokinetic studies, the
latter can be examined by using functional in vitro assays. To
determine the relative potency and specificity of LirAzo
versus Lira, concentration–response curves were recorded for
cAMP generation in CHO cells expressing the GLP-1R
(CHO-GLP-1R).[15] The half maximal effective concentration
(EC50) values for cis-LirAzo (EC50= 262.0 nm) and trans-
LirAzo (EC50= 993.6 nm) were only slightly higher than for
Lira (EC50= 98.9 nm) and GLP-1 (EC50= 20.3 nm ; Figure 2d
and Table S4). Together, these data suggest that the presence
of AMPP does not significantly disturb ligand binding to
GLP-1R.
We next sought to determine the photoswitching proper-
ties of LirAzo in a more relevant system, namely pancreatic
beta cells, in which GLP-1 signals via cAMP and Ca2+ to boost
insulin secretion.[16] By using intact islets of Langerhans, we
confirmed that precise temporal control could be exerted
over intracellular Ca2+ levels (Figure 3a). Whereas trans-
LirAzo induced increases in the baseline amplitude and
frequency of multicellular Ca2+ spiking, this was reduced
following UV (l= 350 nm) illumination to induce cis-LirAzo
accumulation (P< 0.01; Figure 3b–f).
Through alternating exposure to blue (l= 440 nm) and
UV (l= 350 nm) light, oscillations in beta-cell activity, which
are thought to underlie insulin pulses, could be induced
(Figure S5a,b). The effects of trans-LirAzo on Ca2+ levels
were abolished by blockade of the GLP-1R with the specific
antagonist exendin 9–39 (see Figure S5c,d). Furthermore,
trans-LirAzo was unable to stimulate changes in beta-cell
activity in the presence of non-permissive (i.e. low) glucose
concentrations (Figure S5e, f), a prerequisite for proper
incretin action.[4] In all cases, results in islets were recapitu-
lated in immortalized MIN6 beta cells, which are more
amenable to high-throughput assays (see Figure S5g,h).
While cis-LirAzo was able to stimulate Ca2+ fluxes, these
were only just above those observed following control
injection (high glucose alone; see Figure S6).
We next determined the effects of LirAzo on cAMP
generation, another key pathway through which incretins act
Figure 2. Photoisomerization and potency of LirAzo. a) UV/Vis spectra
for cis-(purple) and trans-(blue) LirAzo, as well as Lira (black). Inset:
n–p* band expanded. b) Reversible and repeated toggling of LirAzo
between its cis and trans isomers by using blue (l=440 nm) and UV
(l=330 nm) light. c) Bistability of the cis state over 30 min. d) cAMP
concentration–response studies in CHO-GLP-1R cells, determined by
Promega cAMP-Glo assay. Values plotted are the meanstandard
error of the mean (SEM; n=3 repeats).
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to amplify insulin secretion. As expected
from modeling studies of GLP-1–GLP-
1R binding interactions,[13a,17] cis-LirAzo
displayed different signaling properties to
the trans isomer. The cAMP concentra-
tion response in MIN6 beta cells was
significantly left-shifted, with a higher
maximal response for cis- compared to
trans-LirAzo (Figure 4a,b). Similar
results were observed in CHO-GLP-1R
cells (Figure S7 and Table S4). Robust
signal bias, shown to be a feature of other
GLP-1R agonists,[18] was present at all
LirAzo concentrations over 4 nm (Fig-
ure 4c). Indeed cis-LirAzo favored
cAMP generation, while trans-LirAzo
engaged mainly Ca2+ signaling. Mecha-
nistically, both trans- and cis-LirAzo sig-
naled via the cAMP binding partners Epac2 and PKA, as well
as IP3, a second messenger that mediates the release of Ca
2+
from the endoplasmic reticulum. However, only the former
isomer was able to couple properly to ATP-sensitive K+
channel (KATP) and voltage-dependent Ca
2+ channel
(VDCC) activity (Figure S8a,b). By contrast, Lira triggered
all signaling pathways tested, as expected (Figure S8c). The
minor effects of cis-LirAzo on ionic fluxes are thus mediated
through liberation of Ca2+ from intracellular stores, whereas
trans-LirAzo stimulates Ca2+ influx to support the Ca2+@
cAMP bias.
Given that LirAzo was able to confer light-sensitivity on
GLP-1R signaling, we wondered whether it would also allow
photocontrol of insulin secretion. To examine this, mouse
islets were incubated with LirAzo and exposed to either dark
or light (l= 350 nm). Whereas cis-LirAzo augmented glu-
cose-stimulated insulin secretion equipotently to Lira (ca. 2.5-
fold), trans-LirAzo was much less effective (ca. 1.4-fold;
Figure 5a). This was unlikely to be the result of effects on cell
viability, since cytotoxicity was not detected by either dead:-
live or TUNEL assays following 3 hr exposure of cells to
LirAzo (see Figure S9). Finally, only the trans isomer of
LirAzo was able to offer significant protection from a 24 h
glucolipotoxic insult, which induces beta-cell failure through
apoptosis (Figure 5b).
In the present study, we describe a photoswitchable GLP-
1R agonist based on liraglutide, which allows unprecedented
optical control of a class B GPCR and insulin secretion in
pancreatic beta cells. Intriguingly, signal bias could be
introduced depending on isomerization status, most likely
owing to the pronounced effects of azobenzene orientation on
peptide structure. This phenomenon is well-reported for the
GLP-1R[15,18] and forms the basis of intense research efforts,
since drug side effects may stem from presently unknown
signaling interactions.[19] The GLP-1R is coupled to multiple
pathways (e.g., cAMP, PKA, Epac2, ERK, and b-arrestin),
however, orthosteric ligands can provoke different receptor
conformations to engage distinct signals.[15,18] This is best
exemplified by responses to oxyntomodulin, which is biased
for cAMP over ERK when compared to GLP-1 7–36.[15,18]
Figure 3. Photoswitching of ionic fluxes in pancreatic beta cells.
a–c) Increases in cytosolic Ca2+ levels are larger in LirAzo-treated islets
exposed to blue (trans) versus UV (cis) light (n=8 recordings). d) Pie
charts showing the proportion of beta cells within intact islets that
respond to Lira, trans-LirAzo (blue light), and cis-LirAzo (UV light; n=8
islets). e–f) Positive control showing stimulation of cytosolic Ca2+
levels following the application of Lira but not cis-LirAzo (n=5 record-
ings). Lira/LirAzo were applied at 150 nm in the presence of permissive
(>8 mm) glucose concentration. **P<0.01 versus LirAzo. Values are
given as the meanSEM.
Figure 4. Isomer-biased signaling. a) Photoswitching of cAMP responses in MIN6 beta cells
exposed to Lira, cis-LirAzo, or trans-LirAzo, as determined by Cisbio HTRF cAMP assay (n=7
repeats). b) As for (a), but showing that cis-LirAzo generates significantly more cAMP than
trans-LirAzo at concentrations greater than 102 nm (n=7 repeats). c) Isomer-biased Ca2+
signaling is present at LirAzo concentrations greater than 101 nm (n=8 repeats; Lira shown as
a positive control). Cells were retained in permissive (>8 mm) glucose concentration and Lira
or LirAzo applied at 150 nm. *P<0.05, **P<0.01, and NS (not significant) versus trans-
LirAzo. Values are given as the meanSEM.
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Such divergent effects likely arise from interactions with
specific conserved polar residues.[20]
The fine control offered over GLP-1R molecular path-
ways by LirAzo may hence provide a novel method to tease
apart the mechanisms underlying signal bias in beta cells,
thereby enabling the refinement of incretin mimetics. Indeed,
we were able to show here that cAMP is the major driver of
incretin-potentiated insulin secretion, whereas anti-apoptotic
effects are more pronounced in the presence of both cAMP
and Ca2+. This has repercussions for the design of specific
GLP-1R agonists, since stimulation of both pathways is likely
to be beneficial for T2D treatment. While LirAzo potency
was less than for native liraglutide, it should be noted that
concentration–response studies in CHO and MIN6 cells do
not translate well to islets of Langerhans, where the effects of
GLP-1 on secretion have been detected in the low picomolar
range.[21] Lastly, LirAzo demonstrated excellent bistability,
which facilitates its use in biological studies by circumventing
the need for complex imaging setups/expensive light sources.
In summary, LirAzo provides a blueprint for the produc-
tion of anti-diabetic peptides for which light-triggered alter-
ations to peptide folding—emanating from an azobenzene
unit wedged between the helices—alters GPCR activity. We
anticipate that this, or future variants, may serve as a useful
tool for the functional dissection of GLP-1R signaling in
health and disease.
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